Ferinject or CosmoFer

Phase 2Small molecule

Ferinject or CosmoFer is one of 9 small molecule programs targeting Idiopathic Pulmonary Arterial Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary Arterial HypertensionActive, not recruiting

Idiopathic Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Idiopathic Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Uptravi

Remodulin

Jardiance

Plavix

1 5

Bayer Aspirin

Bayer

Phase 2

1 6

Aerosolized Iloprost

HHeidelberg University

Approved

1 7

Proair HFA

GGlaxo Dba Glaxosmithkline

Phase 2

1 8

Zebeta

Teva

Phase 1

—9

Ferinject or CosmoFer

IImperial College London

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Arterial Hypertension1 trial

IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients

Completed·IImperial College London·Phase 2·NCT01447628·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ferinject or CosmoFer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ferinject or CosmoFer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ferinject or CosmoFer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imperial College London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImperial College London

Ferinject or CosmoFer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Idiopathic Pulmonary Arterial Hypertension1 trial

References

Drug Info

Quick Facts

Related News